Table 7.

Adverse event rate per patient based on STK pathways (clinical trial cohort).

	Grades 1–4				Grades 3 and 4
	Aurora kinase	mTOR-AKT-PI3K	MAPK-MEK-Raf		Aurora kinase	mTOR-AKT-PI3K	MAPK-MEK-Raf
Subject no. (n)	65	75	286	P value	65	75	286	P value
Blood/Lymphatic disorders	2.8	1.7	1.3	0.024	1.3	<0.1	0.4	0.012
Cardiac disorders	0	<0.1	0.1		0	<0.1	<0.1
Constitutional	0	0.6	0.3		0	<0.1	<0.1
Endocrine disorders	0	0	<0.1		0	0	0
Eye disorders	0	<0.1	<0.1		0	0	<0.1
Gastrointestinal disorders	1.9	1.8	1.1		0.1	0.3	0.1
General disorders/administration site conditions	0.8	0.3	0.5		<0.1	<0.1	<0.1
Immune system disorder	0	<0.1	<0.1		0	0	<0.1
Infections and infestations	0	0.1	<0.1		0	<0.1	<0.1
Investigations	0.7	0	0.2		<0.1	0	<0.1
Metabolism and nutrition disorders	1.1	0.5	0.6		<0.1	0.1	0.1
Musculoskeletal and connective tissue disorders	0	<0.1	<0.1		0	<0.1	<0.1
Neoplasms benign, malignant, and unspecified	0	0	<0.1		0	0	<0.1
Nervous system disorders	0	0.2	0.3		0	0	<0.1
Pain	0	0.5	0.2		0	0.1	<0.1
Renal and urinary disorders	0	<0.1	<0.1		0	<0.1	<0.1
Reproductive system and breast disorders	0	<0.1	<0.1		0	0	0
Respiratory, thoracic, and mediastinal disorders	0	0.4	<0.1		0	<0.1	<0.1
Skin/Subcutaneous tissue disorders	0.4	0.5	0.9		0	<0.1	0.2
Syndromes	0	0	<0.1		0	0	<0.1
Vascular disorders	0	0	0.2		0	0	<0.1

Krsukal–Wallis test for P values (comparison across the three groups). Rates of adverse events per patient were calculated by adding all patients experiencing adverse events in a particular organ system class and dividing by the total number of patients exposed to the drug regimen.

STK: Serine–threonine kinases; mTOR: mammalian target of rapamycin; AKT: protein kinase B; PI3K: phosphatidylinositol 3-kinase; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein kinase kinase.